Drug intelligence / Profile preview

GSI-1901

Development stage: Preclinical
Lead developer: Globin Solutions
Modality: Recombinant Proteins and Enzymes

Overview

GSI-1901 is a recombinant protein drug candidate initially developed by Globin Solutions. It is being investigated primarily for the treatment of carbon monoxide poisoning. The drug's mechanism of action and specific molecular target have not been publicly disclosed as of the latest available information. Its development status remains in preclinical or pending stages, with no reported clinical trial results or regulatory approvals to date[1][2].

Beyond the preview

Go deeper on GSI-1901.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GSI-1901.

Explore the full profile